AI-generated summary
The authors compared photothermal-activated platelet-rich plasma with conventional platelet-rich plasma for melasma in a split-face randomized trial of 26 women over three monthly sessions. Both treatments significantly reduced the modified Melasma Area and Severity Index by week 12 with no between-group differences, while only the photothermal-activated version showed a lower melanin index than conventional treatment at week 12. Mild bruising was the only adverse event reported.
- Participants
- 26
- Who or what was studied
- Women with epidermal or mixed-type melasma
- Limits stated in the abstract
- The abstract reports a small single-center sample, and the authors describe the photothermal-activated treatment as a possible alternative rather than a proven one.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Randomized controlled trial, Melanin, Photobiomodulation, Trial registration, Adverse event. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.